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ABBREVIATIONS 
 
DLZ = device landing zone 
LCC = left coronary cusp 
LVOT = left ventricular outflow tract 
MDCT = multidetector computed tomography 
NCC = non-coronary cusp 
PCI = percutaneous coronary intervention 
PVL = paravalvular leak 
RCC = right coronary cusp 
ROI = region of interest 
TA = transapical 
TAVI = transcatheter aortic valve implantation 
TTE = transthoracic echocardiography 
TEE = transesophageal echocardiography 
TF = transfemoral 
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ABSTRACT 
 
Objective. To assess risk factors for paravalvular leak (PVL) after transcatheter aortic valve 
implantation (TAVI) in a large single-center cohort, including measurement of aortic valve 
calcification using a reproducible method. 
Methods. We retrospectively analyzed preoperative contrast-enhanced multidetector computed 
tomography (MDCT) scans of patients who underwent TAVI in our center between 2009 and 2016. 
Calcium volume was calculated for each aortic cusp in the aortic valve (AV), left ventricular 
outflow tract (LVOT) and device-landing zone (DLZ).  
Results. Overall, 539 patients were included in the study (Edwards SapienXT, n=192; Edwards 
Sapien3, n=206; Medtronic CoreValve EvolutR, n=44; Symetis Acurate, n=97). Median calcium 
volume in the DLZ was 757 mm3, with no significant differences among the four prosthesis groups. 
None of the patients had severe PVL. The overall incidence of mild-to-moderate PVL was 15.8% 
(95% CI: 12.8-19.1%). On multivariate logistic regression, DLZ calcification (p=0.00006; OR for 
an increase of 100 mm3 1.08; 95% CI: 1.04-1.13) and use of the CoreValve (p=0.0028; OR 4.1; 
95% CI: 1.6-10 with SapienXT as reference) prosthesis were found to be associated with ≥mild 
PVL. In contrast, degree of oversizing (p=0.002; OR 0.97; 95% CI: 0.95-0.99), and use of Sapien3 
(p=0.00005; OR 0.23; 95% CI: 0.11-0.47 with SapienXT as reference) were associated with a lower 
incidence of ≥mild PVL. 
Conclusions. Aortic calcification volume in the DLZ is associated with residual PVL after TAVI. 
When taking calcification into account, the balloon-expandable prosthesis Sapien3 seems to be 
associated with a lower incidence of PVL. 
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INTRODUCTION 
 
Transcatheter aortic valve implantation (TAVI) has emerged as a new standard for percutaneous 
treatment of severe aortic valve stenosis in intermediate and high surgical risk or inoperable patients 
[1]. However, its wide application is yet limited by the occurrence of postoperative paravalvular 
leak (PVL), which portends increased mortality during follow-up [2]. Aortic valve calcification has 
been found to be associated with PVL [3-6], but results from the available literature have been 
obtained in studies with limited sample sizes [7] or affected by several bias, including methods for 
calcium determination [8] or center effect in multicenter studies [9].  
The aim of this study was to assess risk factors for PVL after TAVI in a large single-center cohort, 
including aortic valve calcification as measured by contrast-enhanced multidetector computed 
tomography (MDCT).  
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METHODS 
 
Study population 
We retrospectively analyzed our center experience with TAVI procedures between July 2009 and 
October 2016. All patients who underwent TAVI for symptomatic severe stenosis of the native 
aortic valve were included in the study. Severe aortic stenosis was defined in accordance with 
international guidelines [1]. Exclusion criteria were: bicuspid aortic valve, pure aortic regurgitation, 
and aborted procedures because of annulus diameter of >30 mm. Overall, 659 patients were eligible 
for the study. However, 108 patients had not a MDCT scan (by first patients was not yet a standard) 
or was performed 5 years previously and MDCT images were not retrievable from our “Picture 
Archiving and Communication System”; 4 patients had no preoperative contrast-enhanced MDCT 
because of severe renal impairment; 3 patients did not have ECG-triggered MDCT scans and were 
unsuitable for analysis; and 5 patients were treated with an experimental second-generation 
prosthesis. Thus, a total of 539 patients were evaluable (Figure 1). Clinical and operative data were 
prospectively collected in our institutional database. The following intraoperative outcomes were 
recorded based on the Valve Academic Research Consortium-2 recommendations [10]: unplanned 
cardiopulmonary bypass, conversion to surgery, coronary obstruction, prosthesis valve 
malpositioning, second prosthesis implantation, and intraoperative percutaneous coronary 
intervention (PCI). All patients provided written informed consent for the use of their data 
anonymously, and the study was approved from our institutional review board (IRB-2017-006). The 
study protocol conforms to the ethical guidelines in the Declaration of Helsinki. 
 
The Heart Team 
According to international guidelines [1], indication for TAVI is discussed within a Heart Team, 
composed of at least a cardiologist and a cardiac surgeon evaluating patients with severe aortic 
valve stenosis, including those referred to our center from peripheral hospitals, private practices, or 
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our emergency department. All patients with frailty factors who were judged inoperable or at high 
surgical risk (as defined by logistic EuroSCORE>20%) were considered eligible for TAVI.  
 
MDCT Angiography and calcium quantification 
All patients underwent contrast-enhanced ECG-gated MDCT (330 ms rotation, helical mode, 60-
70% gating, 0.6x64 mm collimation, 50-100 ml of i.v. contrast agent [Solutrast 370, Bracco 
Imaging Deutschland GmbH] at 4 ml/s) for assessment of aortic root anatomy (suitability for 
TAVI) and the femoral axis (suitably for transfemoral [TF] approach). In our center, all MDCT 
studies were performed with a 64-slice SOMATOM Definition AS (Siemens Healthcare GmbH, 
Erlangen, Germany) and were analyzed by the Heart Team using 3mensio Structural Heart software 
(v.7.0 SP1, Medical Imaging BV, Bilthoven, the Netherlands), which allowed assessment of the 
basal plane (aortic annulus), defined as the virtual plane crossing the nadir of each aortic cusp in 
diastole. 
Calcium volume in the aortic valve was retrospectively measured using 3mensio. After 
identification of the basal plane, the lower coronary ostium was determined and the region of 
interest (ROI) was set before the origin of the coronary vessel. 3mensio software automatically 
performs aortic valve cusp delineation and detects all calcified areas for the selected Hounsfield 
unit (HU) threshold at each of the three cusps. Correct boundary delineation of the left (LCC), right 
(RCC) and non-coronary cups (NCC) was checked at the coaptation point, with manual adjustment 
if necessary. Then, ROI was moved 10 mm below the basal plane in the left ventricular outflow 
tract (LVOT). For the purpose our study, calcium volume was assessed in three different ROIs: (i) 
in the aortic valve; (ii) in the LVOT—these two ROIs were considered either as a whole or for each 
cusp separately; (iii) in the device landing zone (DLZ), defined as the sum of the first two (Figure 
2). The threshold for calcium detection was set to two different cut-off values depending on the 
average HU of blood in the ascending aorta. For values between 130 and 300 HU, a threshold of 
500 HU was chosen, in line with previous studies [3,9]. In contrast, for values between 300 and 600 
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HU (46 patients), an empiric threshold of 800 HU was chosen. Measurements of calcium volume 
were performed by a cardiac surgeon experienced in TAVI and trained in the use of 3mensio (F.P.). 
Interobserver variability was tested for the first 20 cases by a second cardiac surgeon (S.P.) and was 
4.8%.  
The degree of over- or undersizing was calculated as prosthesis valve area (provided by the 
manufacturer)/MDCT annular area. Prosthesis valve area was derived according to the geometrical 
rule: A=π(d/2)2, where d is the labeled prosthesis size. Aortic annulus eccentricity index was 
calculated as 1–(minimal diameter/maximal diameter) based on MDCT annular measurements [11]. 
 
Paravalvular leak quantification 
PVL was quantified by intraoperative transesophageal echocardiography (TEE) performed by a 
dedicated cardiac anesthesiologist under supervision of a cardiologist. In order to obtain maximum 
accuracy, a multiwindow and multiparametric (qualitative and quantitative) approach was applied 
to assess PVL severity [12]. The PVL was categorized as 0=none, 0.5=trace, 1=mild, 1.5=mild to 
moderate, 2=moderate, 2.5=moderate to severe, and 3=severe. 
 
Procedure 
TF-TAVI was preferred as first choice in all patients without severe peripheral artery disease and 
with suitable femoral axis. Alternatively, the transapical (TA-TAVI) access was used. All 
procedures were conducted in a hybrid operating room under fluoroscopic control (Artis Zeego 
System, Siemens AG, Erlangen, Germany), general anesthesia, periprocedural TEE, and a cardiac 
perfusionist with ready-to-use cardiopulmonary bypass on site. All implants were performed by a 
multidisciplinary team composed of at least a cardiologist (procedure leader in case of TF-TAVI) 
and a cardiac surgeon (procedure leader in case of TA-TAVI). Four different prostheses are 
routinely implanted in our center: SapienXT and Sapien3 (Edwards Lifesciences Inc., Irvine, CA), 
CoreValve/EvolutR (Medtronic, Minneapolis, MN), and Acurate TA/NeoTF (Symetis SA, 
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Ecublens, Switzerland). Selection of prosthesis type is agreed preoperatively with the cardiologist 
and cardiac surgeon on the basis of several parameters, including need for elective PCI after TAVI, 
annulus dimension, and distance from the aortic annulus to the coronary ostia. Definitive selection 
of prosthesis size is usually agreed intraoperatively by the Heart Team after evaluation of MDCT 
(annular perimeter-derived dimensions), TEE and angiographic parameters (e.g. contrast reflux 
during valvuloplasty, balloon sizing). 
 
Statistical analysis 
Data consistency was checked and data were screened for outliers and normality by using quantile 
plots. Continuous variables were also tested for normality by using Kolmogrov-Smirnov test. 
Categorical variables are expressed as frequencies (percentages) and continuous variables as mean 
(±standard deviation) or median (interquartile range). In order to assess the performance of different 
prosthetic valves in different calcification patterns, the study population was divided into four 
groups according to the implanted prosthesis. Differences between groups were determined by 
ANOVA testing with Bonferroni correction and Kruskal-Wallis test. Cross tabulation tables with 
Kruskal-Wallis test for singly ordered variables. Potential risk factors for the occurrence of ≥mild 
PVL, including CT, baseline and operative parameters of patients were entered in the univariate and 
multivariate logistic regression models. The dependent variable of the logistic model was the 
occurrence of PVL. A univariate analysis was first performed. Variables with p<0.2 were included 
in a multivariable logistic model regression analysis using stepwise selection algorithm 
(hierarchical forward with switching) to identify the predictors of PVL. Odds ratios with 
corresponding 95% confidence intervals were computed in each model. The discrimination 
achieved was assessed with the C statistic, which is equivalent to the area under the receiver 
operating characteristic curve. A generalized linear model for PVL location was built to analyze the 
relation between calcium distribution across the aortic cusps (based on the multinomial distribution 
for PVL location). 
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Clinical, procedural, echocardiographic, and preoperative MDCT variables were entered into 
univariate analysis. A receiver operating characteristic (ROC) curve was calculated from the DLZ, 
allowing assessment of cutoff values defining ≥mild PVL. All reported tests were two-sided, and p-
values <0.05 were considered as statistically significant. All statistical analyses in this report were 
performed by use of NCSS (NCSS 10, NCSS, LLC. Kaysville, UT), STATISTICA 13 (Hill, T. & 
Lewicki, P. Statistics: Methods and Applications. StatSoft, Tulsa, OK) and PASW 23 (IBM SPSS 
Statistics for Windows, Version 21.0, Armonk, NY).  
 
  
11 
RESULTS 
 
Patient clinical and procedural characteristics are shown in Table 1, and MDCT measurements 
including calcium volume are listed in Table 2, according to the implanted prosthesis. The TF 
access route was most frequently used for TAVI (67% of cases). All groups had a mean logistic 
EuroSCORE>20%. Calcium volume in the DLZ varied from a minimum of 17.5 mm3 to a 
maximum of 4523 mm3. Significant differences among the prosthesis groups were observed in New 
York Heart Association class, size of prosthesis used, valve area, annulus perimeter, distance 
between the coronary ostia and annuli, and oversizing. Calcium volume in the DLZ and in the 
diverse subsectors did not significantly differ among groups. 
Figure 3A shows the incidence of PVL by prosthesis group. Overall, 199 (36.9%) patients had an 
intraoperative leak (from trace to moderate). No patient presented severe or moderate to severe 
PVL. Patients implanted with the Sapien3 valve had the lowest incidence and degree of PVL. The 
distribution of calcium volume in the DLZ for patients with none, trace, mild and moderate PVL are 
showed in supplementary figure 1 according to valve prosthesis. Logistic regression model (C-
statistic=0.809; 95% CI 0.771-0.843; Table 3), based on preoperative variables of Table 1 and 2, 
identified DLZ calcification and use of CoreValve/EvolutR prosthesis as associated with ≥mild 
PVL. On the other hand degree of oversizing and use of Sapien3 were associated with a lower 
incidence of ≥mild PVL. The discriminating power of DLZ calcification was evaluated by C-
statistic and ROC curve analysis. The area under the ROC curve (Supplementary Figure 2) was 0.66 
(95% confidence interval 0.617–0.699, p=0.0001) for ≥mild PVL. The ROC analysis identified the 
cutoff value of 1079 mm3 (sensitivity 53%; specificity 75%) for DLZ calcification, above which a 
significantly increased risk of ≥mild PVL was observed. Differences in PVL incidence for DLZ 
higher or lower than 1079 mm3 are shown in Figure 3B for each prosthesis group. A DLZ calcium 
volume >1079 mm3 was associated with a significantly higher incidence of ≥mild PVL in all 
prosthesis groups (p<0.05). 
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Table 1. Baseline and procedural characteristics 
 
Total (=539) Sapien XT (=192) Sapien 3 (=206)   CoreValve/EvolutR (=44) Symetis (=97)    
 N Mean-% SD N Mean-% SD N Mean-% SD N Mean-% SD N Mean-% SD p 
Age (years)   81.70 6.04  81.82 6.43   81.97 5.48   80.09 7.72  81.62 5.51 0.30 
Female gender 272 50%  96 50%  103 50%  21 48%  52 54%  0.91 
BMI (kg/m2)   27.18 4.82  27.07 4.75   27.02 4.78   27.05 4.86  27.79 5.05 0.59 
Creatinine (mg/dl)   1.50 0.95  1.47 0.89   1.47 0.79   1.28 0.54  1.71 1.38 0.06 
Creatinine clearance (ml/min)   44.71 19.46  44.67 19.34   44.29 18.38   50.26 20.49  43.16 21.25 0.23 
Extracardiac arteriopathy 145 27%  50 26%  55 27%  8 18%  32 33%  0.31 
Previously cardiac surgery 111 21%  47 24%  33 16%  10 23%  21 22%  0.21 
Previously CABG 94 17%  36 19%  28 14%  10 23%  20 21%  0.28 
Chronic lung disease 101 19%  40 21%  38 18%  7 16%  16 16%  0.77 
NYHA   3.02   3.11    2.96    2.98   3.01  0.02 
Ejection fraction (%)   52.62 12.97  53.14 13.68   52.47 12.85   49.05 12.30  53.55 11.94 0.24 
Recent myocardial infarction 16 3%  10 5%  4 2%  0 0%  2 2%  0.13 
Severe PHT (>60 mmHg) 181 34%  68 35%  75 36%  12 27%  26 27%  0.31 
Additive EuroSCORE   10.41 2.56 
 
10.59 2.65   10.40 2.62   9.77 2.74 
 
10.37 2.10 0.30 
Logistic EuroSCORE   23% 0.15 
 
24% 0.16   23% 0.16   21% 0.15 
 
22% 0.13 0.41 
EuroSCORE II   9% 0.07 
 
9% 0.08   9% 0.08   8% 0.06 
 
8% 0.06 0.36 
TF access 360 67%  118 61%  155 75%  44 100%  43 44%  <0.001 
Prosthesis size                <0.001 
 23 mm 175 32.5%  61 31.8%  84 40.8%  0   30 30.9%    
 25 mm 33 6.1%       
 
   
 
33 34% 
 
  
 26 mm 192 35.6%  91 47.4%  91 44.2% 
 
10 22.7% 
 
  
 
  
 27 mm 34 6.3%       
 
  
 
34 35% 
 
  
 29 mm 83 15.4%  40 20.8%  31 15% 
 
12 27.3% 
 
  
 
  
 31 mm 22 4.1%       
 
22 50% 
 
  
 
  
Valvuloplasty pre-implant 527 97.8%  189 98.4%  202 98.1% 40 90.9% 96 99% 0.01 
Implant rapid pacing 413 76.6%  192 100%  206 100%  4 9.1%  11 11.3%  <0.001 
Balloon dilation post-implant 184 34.1%  75 39.1%  53 25.7%  14 31.8%  42 43.3%  0.01 
BMI=body mass index; CABG=coronary artery bypass graft; Chronic lung disease=use of bronchodilators; NYHA=New York Heart Association; PHT=pulmonary hypertension; TF=transfemoral. 
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Table 2. MDCT measurements. 
 
Total Sapien XT Sapien 3 CoreValve/EvolutR Symetis  
 
Median IQR Median IQR Median IQR Median IQR Median IQR p 
Annulus area (cm2) 4.60 3.9-5.28 4.51 3.82-5.12 4.64 4.08-5.42 5.39 4.15-6.03 4.49 3.78-4.98 <0.001 
Annulus perimeter (mm) 77.50 71.8-83.5 76.55 70.95-82.8 78.60 72.75-84.3 83.70 74.37-88.77 76.50 70.45-81.35 <0.001 
Distance annulus-RCA (mm) 15.40 13-18 17.00 14.32-19.2 14.55 12.6-17.2 15.00 12-17.7 14.40 11.8-17.5 <0.001 
Distance annulus-LCA (mm) 13.40 11.6-15 13.60 12-15.5 14.00 11.05-15 12.90 11-15.37 13.00 11-15 0.04 
Oversizing (%) 12% 3.2-23 15% 6.1-27.2 7% -0.65-14.3 34% 21.9-45.5 11% 6.8-20.4 <0.001 
Eccentricity index 0.19 0.14-0.23 0.19 0.13-0.23 0.19 0.15-0.23 0.19 0.13-0.22 0.19 0.15-0.24 0.51 
DLZ calcium (mm3) 757.00 442-1176 748.10 419-1171 756.10 477-1174 976.80 561-1446 649.00 391-1086 0.06 
Total calcium-AV (mm3) 683.00 412-1082 655.20 409-1023 698.2 433-1094 917.45 482-1323 633.60 356-1073 0.07 
LCC calcium-AV (mm3) 188.80 95-327 173.60 84-305 186.4 102-337 251.60 104-363 176.80 104-308 0.26 
RCC calcium-AV (mm3) 178.70 89-312 181.85 84-313 188.4 120-303 190.40 85-417 139.20 67-296 0.15 
NCC calcium-AV (mm3) 289.60 161-452 273.50 155-439 290.75 171-460 390.35 155-578 276.60 157-439 0.05 
Total calcium-LVOT (mm3) 18.00 1.37-85 12.70 0.025-77 17.70 2-68.85 48.30 6.1-190.8 22.70 1.6-91.25 0.26 
LCC calcium-LVOT (mm3) 2.05 0-34 0.40 0-23.82 1.60 0-31.1 5.2 0-88.57 5.1 0.1-48.45 0.34 
RCC calcium-LVOT (mm3) 0.00 0-1.2 0.00 0-0.1 0.10 0-2.75 0.05 0-6.87 0.00 0-0.55 0.49 
NCC calcium-LVOT (mm3) 2.00 0-24 0.90 0-20.75 2.20 0-24.55 15.95 0.22-62.07 1.80 0-18.6 0.05 
AV=aortic valve; DLZ=device landing zone; LCA=left coronary artery; LCC=left coronary cusp; LVOT=left ventricular outflow tract; NCC=non-coronary cusp; RCA=right coronary artery; RCC=right 
coronary cusp. 
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Table 3. Independent factors for paravalvular leak at logistic regression analysis. 
Univariate model Multivariate model (stepwise) 
 p-value OR 95% CI OR 95% CI p-value 
Ejection fraction (%) 0.14 0.99 0.97 1.00 - - - - 
Annulus diameter Max (mm) 0.002 1.14 1.05 1.24 - - - - 
Annulus diameter Min (mm) 0.02 1.12 1.02 1.23 - - - - 
Annulus area (cm2) 0.001 1.51 1.18 1.93 - - - - 
Annulus perimeter (mm) 0.004 1.05 1.01 1.08 - - - - 
Oversizing (%) 0.039 0.98 0.97 1.00 0.97 0.95 0.99 0.002 
LCC calcium-AV (mm3) 0.00003 1.00 1.00 1.00 - - - - 
NCC calcium-AV (mm3) 0.00001 1.00 1.00 1.00 - - - - 
LCC calcium-LVOT (mm3) 0.054 1.00 1.00 1.00 - - - - 
NCC calcium-LVOT (mm3) 0.0003 1.01 1.00 1.01 - - - - 
Female gendera 0.011 0.54 0.33 0.87 - - - - 
Dialysis (preoperative) 0.19 0.26 0.03 1.95 - - - - 
TA accessb 0.015 1.79 1.12 2.88 - - - - 
Sapien XTc - 1 - - 1 - - - 
Sapien 3  0.001 0.34 0.18 0.65 0.23 0.11 0.47 0.00005 
CoreValve/EvolutR 
 
0.019 2.69 1.17 6.17 4.09 1.62 10.3 0.003 
 Symetis  0.23 1.44 0.80 2.62 1.29 0.68 2.43 0.44 
DLZ calcium (mm3)d < 0.00001 1.09 1.05 1.13 1.08 1.04 1.12 0.00006 
a) reference is male. b) reference transfemoral. c) reference is Sapien XT. d) OR is rescaled to 100 mm3. 
AV=aortic valve. DLZ=device landing zone; LCC=left coronary cusp; LVOT=left ventricular outflow 
tract; NCC=non-coronary cusp; TA=transapical. 
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Among the 199 patients with PVL, data on annular leak location were missing in 33. In the 
remaining 166 patients, the lowest incidence of PVL was detected in the RCC (5.4%), which also 
had less calcium volume in the LVOT. PVL was located more frequently in the LCC (59.6%), 
followed by the NCC (26.5%). In the remaining 8.4% of cases, it occurred at the commissure level 
(LCC/NCC 5.4%; NCC/RCC 0.6%; RCC/LCC 2.4%). On generalized linear model (multinomial 
model) no significant relations were found between PVL location and calcium distributions across 
the aortic cusps. 
 
Other intraoperative complications and outcome 
Prosthesis migration or malpositioning occurred in 6 cases (3 SapienXT [TA-access], 2 Symetis 
[TA-access], 1 CoreValve [TF-access]), seemingly unrelated to calcium volume (mean DLZ 
calcium 785 mm3; 171–1338) but to a low level of oversizing (median 9.7%). Three patients 
underwent emergent surgical aortic valve replacement (AVR) following explantation of the TAVI 
device. Three patients underwent emergency valve-in-valve implantation with good results in 2 and 
conversion to surgical AVR in 1. All 6 patients survived the procedure. 
Annular rupture occurred in 2 patients (DLZ calcium of 2828 and 613 mm3, respectively, with 
intraprocedural death in one case, and discharge to home in the other). Coronary obstruction as 
isolated complication (unrelated to prosthesis migration) occurred in 2 cases (DLZ calcium of 1044 
and 156 mm3, with Sapien XT), requiring emergency PCI in one case and coronary artery bypass 
graft in the other case. Overall, immediate and 30-day mortality was 0.93% (n=5) and 5.38% 
(n=29), respectively. 
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DISCUSSION 
 
Our study evaluated post-implant PVL occurrence and grade using a multimodality approach that 
included measurement of aortic valve calcification. On the basis of our results: 
(i) DLZ calcification plays a key role in PVL occurrence after TAVI, and routine 
determination of calcium volume with a quantitative and reproducible measurement may 
provide additional useful information for planning interventions; 
(ii) in presence of extensive DLZ calcifications and increased risk of PVL, the procedural 
strategy should be modified accordingly, trying to reduce the burden of other 
contributing but controllable factors (e.g.: oversizing and choice of prosthesis); 
(iii) CoreValve prosthesis is more vulnerable and perform less efficiently in the presence of 
severe calcification. 
 
The use of MDCT has become routine for transcatheter heart valve sizing and procedural planning 
[1]. Given the availability of improved imaging software and the widespread use of TAVI, we 
adopted a new approach to extract the most information from MDCT and achieve the best possible 
outcome.  
The presence of even mild residual PVL in high-risk patients was found to be associated with a 
significantly worse survival compared to that of patients who did not exhibit such complication, up 
to 5-year follow-up [2]. In intermediate-risk patients, this tendency was also observed for 
≥moderate PVL [13]. The incidence of ≥mild PVL varies across studies, ranging from 44% to 77%, 
with ≥moderate PVL ranging from 3.1% to 21.6% [14,15]. In our study, greater than mild PVL was 
observed in 15.76% of patients, with 1.4% of them experiencing moderate PVL and none severe 
PVL, which is significantly lower than the incidence reported in the literature. In our opinion, two 
factors may account for this discrepancy. First, the use of new prostheses: a direct comparison 
between SapienXT and Sapien3, where the latter is a further development of the former and was 
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used in the majority of our study patients, seems to confirm that the improvements introduced in the 
newer generation valves (e.g. annular skirt) have fulfilled the predetermined purpose of reducing 
PVL occurrence, as also demonstrated in the SOURCE-3 Registry [14]. Second, the higher use of 
balloon post-dilation (34.13%): this is the result of our team’s choice of low tolerance of ≥moderate 
PVL, which proved to be safe, with only one case of annular rupture among patients who 
underwent balloon post-dilation. 
Our study aimed at identifying a practical method for pre-procedural calcification assessment. The 
critical value above which all prosthesis models proved to be vulnerable seems >1000 mm3, taking 
as reference PVL of mild or greater degree. Despite the sensitivity and specificity of this threshold 
are not optimal, this finding is consistent with previous research [3]. In every case, the low 
incidence of other intraoperative complications, apparently unrelated to the degree of calcification, 
confirms that TAVI remains a safe procedure. 
To the best of our knowledge, this study is the largest to assess calcium volume in patients 
undergoing TAVI. Studies based on reproducible and quantitative methods (or dedicated software) 
for quantification of aortic valve calcification have so far been scant, with limited sample size or 
several potential biases. 
In 123 patients implanted with an Edwards Sapien/SapienXT valve (23 and 26 mm), Jilaihawi and 
colleagues [4] tested the reliability of contrast-enhanced MDCT for calcium quantification at 
multiple thresholds for detection compared with the traditional Agatston scoring used for non-
contrast MDCT scans. On multivariate analysis, prosthesis undersizing and presence of LVOT 
calcium were predictors of PVL. 
In a retrospective study, Koh et al. [7] evaluated 56 patients who underwent TAVI with TA or 
transaortic delivery of an Edwards Sapien valve (no longer commercially available). Calcium 
volume was significantly higher in patients with PVL, but no correlation was found with PVL 
grade. However, these findings were not supported by multivariate analysis. 
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Seiffert and colleagues [9] evaluated the impact of calcium volume on PVL using a similar method 
to ours and reported comparable median calcium volumes (619 mm3 in the aortic valve and 11 mm3 
in the LVOT). DLZ calcium, particularly if located in the LVOT, was predictive of PVL. In the 
Seiffert study, however, a higher incidence of PVL was observed. As this was a two-center study, 
one possible reason accounting for this finding is a center effect, which was also identified at linear 
regression analysis. Another aspect that deserves consideration is the low number of implants of 23 
mm valves performed in their patients. In addition, in their study, only next-generation transcatheter 
aortic prostheses for TA access (e.g. JenaValve, Engager) were used, equipped with a peculiar 
implant system. Further, no balloon-expandable Sapien3 prosthesis was used in their study, which 
on the contrary accounts for 38% of the prostheses used in our study and implanted via TF access in 
75% of cases. Similarly to the experience of Seiffert et al. [9], the CoreValve prosthesis was 
associated with a higher incidence of PVL. Although no small-sized CoreValve prostheses (23 mm) 
were used in our population, multivariate analysis has ruled out annular size as a risk factor for 
PVL. This means that the high incidence of PVL in this group cannot be explained solely by its use 
in large aortic annuli. Additionally, the CoreValve group was the one with the highest degree of 
oversizing, which was found to be a protective factor for subsequent PVL. An explanation may lie 
in the peculiar radial forces of the CoreValve Nitinol stent. The Figure 4 shows an emblematic 
example of how a severe calcification, despite 34% of oversizing, can result in a non-correctable 
PVL, even after post-dilatation, in a CoreValve prosthesis. It should be noted that only 
intraoperative TEE was evaluated as it is highly accurate in discriminating PVL from central 
regurgitation and our study was focused solely on the acute outcome. However, it has been 
demonstrated that incidence and severity of PVL after CoreValve implantation tend to diminish 
over time, showing a significant reduction after 1 year [16]. Incidence of PVL at discharge 
(assessed through TTE) in our series is showed in Supplementary Figure 3 and Supplementary 
Table 1. Bearing in mind the inferiority of the TTE with respect to the TEE, we did not observe any 
reduction in the incidence of ≥mild PVL. 
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Localization of PVL 
Although our analysis confirmed that aortic calcification is crucial in determining post-implant 
PVL, less clear conclusions can be drawn regarding PVL location. A very low incidence of PVL 
was observed in the RCC. One possible explanation for this finding is that the RCC is positioned 
above the interventricular septum, which is probably a more stable cardiac structure allowing better 
sealing compared with the left and right fibrous trigone with which the LCC and NCC, respectively, 
are in direct continuity. However, the fact that PVL was found to be most frequently located in the 
LCC despite higher calcium volume along the NCC, remains unexplained. This may be due to (i) 
confounding factors (e.g. radial force distribution of the different stent designs) that, along with 
calcification, may contribute to determine the location of PVL, or (ii) a bias in reporting localization 
of PVL. Given that the valve systems used in our study do not provide an anatomical orientation of 
the prosthesis into the aortic annulus, the exact recognition of the native cusps is difficult after 
implantation. Fluoroscopy provides only a two-dimensional projection, and the use of intraoperative 
three-dimensional TEE is not routine practice in our institution. Notwithstanding this, future 
prospective studies using intraoperative three-dimensional imaging are required to address the issue 
of PVL localization. 
 
Study limitations 
Several limitations should be acknowledged in this study. First, the method used for assessing aortic 
calcification. Previous studies investigated the reliability of contrast-enhanced MDCT and different 
thresholds with non-enhanced MDCT [4]. Unfortunately, the results of contrast-enhanced MDCT 
remain strongly dependent on the selected HU threshold. Indeed, the choice of testing blood HU in 
the ascending aorta was intended to avoid relevant mistakes deriving from the indiscriminate use of 
the same threshold for all study patients. The selected threshold of 500 HU (and 800 HU in some 
cases) is arbitrary and needs to be validated, although adopted in previous similar studies [3,4,9]. 
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Second, differences in prosthesis groups, where a greater expertise in balloon-expandable 
prostheses was likely. Third, extended calcifications may be hiding undetected bicuspid aortic 
valves that could be account as confounding factors [17]. Fourth, the retrospective nature of our 
study, which calls for the need of randomized prospective studies to validate our findings. Until 
then, suggesting a specific prosthesis for a particular calcification pattern would be imprudent. 
Moreover, the importance of other perioperative complications (e.g. vascular complications, stroke 
and need for permanent pacemaker implantation) should not be underestimated and is currently the 
subject of dedicated studies from our team. 
 
Conclusions 
In conclusion, aortic calcification volume in the DLZ is associated with residual PVL after TAVI. 
When taking calcification into account, the balloon-expandable prosthesis Sapien3 seems to be 
associated with a lower incidence of PVL. 
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FIGURES 
 
Figure 1. Flowchart showing the selection process of the study population. 
 
 
Figure 2. Aortic calcium volume quantification on 3mensio Structural Heart. A: stretched vessel 
view of the aortic valve and ascending aorta with highlighting of the region of interest. The blue 
line identifies the basal plane (aortic annulus). B: transverse view of the native aortic valve with the 
three cusps (yellow=right coronary cusp; cyan=left coronary cusp; magenta=non-coronary cusp).  
AV=aortic valve; DLZ=device landing zone; LVOT=left ventricular outflow tract. 
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Figure 3. A: Incidence of residual paravalvular leak (PVL) in the four prosthesis groups 
(blue=none; green=trace; yellow=mild; orange=mild/moderate; red=moderate) assessed by 
intraoperative transesophageal echocardiography. B: Differences in residual paravalvular leak 
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(PVL) in the four prosthesis groups according to DLZ calcium volume higher or lower than the cut-
off value of 1079 mm3. 
 
 
Figure 4. An emblematic example showing onset of paravalvular leak (PVL) during implantation 
of a 29 mm CoreValve EvolutR prosthesis in an 82-year-old woman with extremely calcified aortic 
valve. A) Calcification of aortic valve on 3mesio multidetector computed tomography scan (Device 
Landing Zone calcium volume: 1622 mm3; Non coronary cusp [NCC]-LVOT calcium volume: 223 
mm3; oversizing: 34%). The white arrow shows NCC-LVOT. B) Intraoperative fluoroscopy: after 
prosthesis deployment, failure of stent expansion in the NCC was evident (white arrow). 
Subsequent balloon dilation allowed adequate stent expansion, but moderate paravalvular leak 
persisted (C, white arrow) at intraoperative transesophageal echocardiography. 
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Supplementary Figure 1. Side-by-side boxplot showing the distribution of calcium volume in the 
DLZ for patients with none, mild, mild/moderate and moderate PVL for each of the implanted 
prosthesis. 
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Supplementary Figure 2. Receiver operating characteristic (ROC) curve analysis for the accuracy 
of device landing zone calcium in predicting ≥ mild paravalvular leak. 
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Supplementary Figure 3. Incidence of residual paravalvular leak (PVL) in the four prosthesis 
groups (blue=none; green=trace; yellow=mild; orange=mild/moderate; red=moderate) assessed by 
transthoracic echocardiography at discharge from hospital. 
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